Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Abivax SA Sponsored ADR ( (ABVX) ).
On May 22, 2026, Abivax reported its first-quarter 2026 results and long-term data from Study 108, an open-label extension trial of obefazimod in moderately to severely active ulcerative colitis. After two to four years on 50 mg, 130 patients de-escalated to 25 mg daily, and as of the January 5, 2026 cutoff, 68% remained in clinical remission at week 144 and 80% completed 144 weeks, with no new safety signals observed over treatment periods of up to seven years.
The company highlighted a solid cash position of €491.6 million as of March 31, 2026, implying a runway into the fourth quarter of 2027, while R&D spending rose to €49.5 million as it pushed obefazimod into new indications and advanced its Crohn’s disease program, even as ulcerative colitis Phase 3 costs began to taper. Abivax also noted higher sales and marketing spend tied to U.S. commercialization preparation and flagged late second-quarter 2026 as the expected timing for Phase 3 UC maintenance topline data, a key milestone for its lead asset and future regulatory strategy.
The most recent analyst rating on (ABVX) stock is a Sell with a $110.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The score is held down primarily by weak operating fundamentals (zero revenue in 2025, widening losses, and heavy cash burn). Technicals also lean bearish with the price below key moving averages and negative MACD. The main stabilizer is the improved balance sheet with low leverage and a larger equity base.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in Paris that develops therapies aiming to harness the body’s natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead drug candidate is obefazimod, being advanced primarily for ulcerative colitis and Crohn’s disease, with a growing focus on potential future commercialization in the U.S. market.
Average Trading Volume: 966,710
Technical Sentiment Signal: Buy
Current Market Cap: $9.52B
See more data about ABVX stock on TipRanks’ Stock Analysis page.